Iomab-B Prior to Allogeneic HCT Improves Durable Complete Remission Rate in Older Patients With R/R AMLFebruary 19th 2023
High initial complete remission with or without platelet recovery, as well as an improvement in durable complete remission was achieved with the use of Iomab-B-based conditioning prior to allogeneic hematopoietic cell transplantation compared with conventional care in older patients with relapsed/refractory acute myeloid leukemia.
Vedolizumab Plus Standard Prophylaxis Reduces Rate of Lower GI aGVHD
The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.
Tisa-cel Reinfusion Shows Potential as HSCT Bridging Therapy in Pediatric B-ALLFebruary 19th 2023
Second infusion with tisagenlecleucel after prior tisagenlecleucel infusion produced short durations of minimal residual disease-negative responses in children and young adults with B-cell acute lymphoblastic leukemia.
Ide-Cel Improves PFS and ORR in Triple-Class Exposed, Early R/R Multiple MyelomaFebruary 19th 2023
Idecabtagene vicleucel demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and objective response compared with standard of care approaches in patients with triple-class-exposed relapsed/refractory multiple myeloma.
Chronic Opioid Use Following ASCT Linked With Poor Survival Outcomes in Multiple MyelomaFebruary 18th 2023
Patients with multiple myeloma who were treated with autologous stem cell transplantation were found to be utilizing chronic opioids at high rates, in turn leading to worse overall survival outcomes at 6 months of follow-up.
Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple MyelomaFebruary 18th 2023
Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.
Dr. Srour on Orca-Q Transplantation in Hematologic MalignanciesFebruary 18th 2023
Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.
Novel Therapies Are Needed to Reduce Cost Burden With AlloHCT, GVHD
Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.
Ruxolitinib Induces High Responses in SR-aGVHD, Regardless of CytopeniasFebruary 17th 2023
The presence of cytopenias did not affect the favorable and durable responses seen with ruxolitinib vs best available therapy in patients with steroid-refractory acute graft-vs-host disease.
Ruxolitinib Provides ORR Benefit vs BAT in Early Treatment of SR-aGVHD
Early treatment with ruxolitinib led to high response rates in patients with steroid refractory acute graft-vs-host-disease, although benefits with ruxolitinib vs best available therapy were observed regardless of the timing of ruxolitinib administration.
Ruxolitinib Displays Variable Pharmacokinetics in Patients with GVHD 2 Years of Age and UnderFebruary 17th 2023
A study did not find a correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib for the treatment of patients 2 years of age and younger with graft-vs-host disease.
Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies
Orca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encouraging outcomes for patients with high-risk hematologic malignancies.
CD22-Directed CAR T-cell Therapy Elicits High CR Rates in LBCL After CD19 Relapse
CD22-directed CAR T-cell therapy generated high complete response rates and manageable safety in heavily pretreated patients with large B-cell lymphoma who relapsed following CD19-directed CAR T-cell therapy.
Salvage Checkpoint Inhibitors Reduce Peri-ASCT Progression in R/R Hodgkin LymphomaFebruary 17th 2023
Checkpoint inhibitor–based salvage regimens significantly reduced the likelihood that patients with relapsed/refractory classic Hodgkin lymphoma undergoing transplant would need further salvage therapy vs conventional salvage regimens.
Orca-T Leads to 100% Survival Rate in Early Trial of Patients With Hematologic Malignancies and 7/8 Mismatched DonorsFebruary 17th 2023
Orca-T produced a 100% overall survival rate in 8 patients with hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors.
Ide-Cel Is Effective, Safe for Patients With R/R Multiple Myeloma and Renal Insufficiency
Patients with relapsed or refractory multiple myeloma treated with the CAR T-cell agent idecabtagene vicleucel had comparable efficacy and safety outcomes regardless of whether they had renal impairment, according to findings from a real-world study.
Dr. Frank on CD22 CAR T-cell Therapy in Relapsed LBCLFebruary 17th 2023
Matthew Frank, MD, PhD, discusses findings from a single-institution phase 1 trial investigating autologous CAR T cells targeting CD22 in adults with large B-cell lymphoma, including those who relapse after or are refractory to CD19-directed CAR T-cell therapy.
Dr. Narkhede on Siltuximab for CRS and ICANS in Hematologic MalignanciesFebruary 16th 2023
Mayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.
Brexu-cel Shows Survival Benefit in Relapsed/Refractory B-cell ALL, Regardless of Prior Treatment
Brexucabtagene autoleucel demonstrated a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of prior lines of treatment or exposure to blinatumomab or allogeneic stem cell transplant, according to data from subgroup analyses of the ZUMA-3 trial.
MRD Detection Provides Prognostic Value in Patients With ALL Undergoing HCTFebruary 16th 2023
The presence of minimal residual disease led to a higher likelihood of relapse in patients with acute lymphoblastic leukemia who underwent hematopoietic cell transplant compared with those who had undetectable MRD pre and post transplant.
Haploidentical Donors/Posttransplant Cyclophosphamide Produces Outcomes Similar to Matched Unrelated Donor Transplantation in Myelofibrosis
Haploidentical donors and posttransplant cyclophosphamide is a comparable alternative to matched unrelated donors for patients with myelofibrosis receiving blood or marrow transplant without matched sibling donors, although matched sibling donors, when available, remain the preferred donor option.
JCAR021 Showcases High Response Rates, but Mixed Safety Data in Relapsed/Refractory Large B-cell Lymphoma
The fully-human scFv CD19-targeted CAR T-cell therapy JCAR021 elicited durable responses but with a high rate of neurotoxicity when administered at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma, according to data from a phase 1/2 trial.
ADI-001 Produces Responses, Favorable Safety in Relapsed/Refractory B-Cell NHL
ADI-001, a first-in-class, allogeneic gamma delta1 CAR T-cell therapy, elicited responses and demonstrated a favorable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Freshly Infused Zamtocabtagene Autoleucel Shows Encouraging Activity in Relapsed/Refractory DLBCLFebruary 16th 2023
The dual CD19- and CD20-directed, freshly administered CAR T-cell therapy zamtocabtagene autoleucel elicited a high response rate with deepening responses over time in patients with relapsed/refractory diffuse large B-cell lymphoma.